Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics and AbbVie. His expertise is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also has an extensive research portfolio of investigational NSAs.
Dr. Kramer’s appointment comes at a pivotal time as the company advances its late-stage clinical programs. His experience in medical affairs will be crucial in guiding the regulatory and clinical strategy for these promising therapies. The full press release can be viewed at https://ibn.fm/FdEXH.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. For company updates, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma is a trademark of Cybin Corp.
